PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 35462930-7 2022 The other patient acquired EGFR T790M and MET amplification post-dacomitinib and acquired CCDC6-RET fusion after osimertinib treatment. osimertinib 113-124 ret proto-oncogene Homo sapiens 96-99 31911548-4 2020 Nineteen percent (5/27) of patients treated with first-line osimertinib had off-target genetic resistance (2 MET amplification, 1 KRAS mutation, 1 RET fusion, and 1 BRAF fusion) whereas 4% (1/27) had an acquired EGFR mutation (EGFR G724S). osimertinib 60-71 ret proto-oncogene Homo sapiens 147-150 33641722-0 2021 Selpercatinib Overcomes CCDC6-RET-Mediated Resistance to Osimertinib. osimertinib 57-68 ret proto-oncogene Homo sapiens 30-33 33173309-5 2020 Conclusion: Our findings expanded the spectrum of RET arrangement types and provided the basis for this hypothesis: acquired RET rearrangement and EGFR exon20 p.T790M loss potentially serve an additional resistance mechanism to osimertinib in EGFR-mutated non-small-cell lung cancer (NSCLC). osimertinib 228-239 ret proto-oncogene Homo sapiens 50-53 33173309-5 2020 Conclusion: Our findings expanded the spectrum of RET arrangement types and provided the basis for this hypothesis: acquired RET rearrangement and EGFR exon20 p.T790M loss potentially serve an additional resistance mechanism to osimertinib in EGFR-mutated non-small-cell lung cancer (NSCLC). osimertinib 228-239 ret proto-oncogene Homo sapiens 125-128 34994624-0 2021 Divergent RET- and BRAF-Mediated Resistance to Osimertinib in EGFR-Mutant NSCLC: A Case Report. osimertinib 47-58 ret proto-oncogene Homo sapiens 10-13 34344199-0 2022 Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC. osimertinib 62-73 ret proto-oncogene Homo sapiens 21-24 34203709-2 2021 Multiple receptor tyrosine kinase (RTK) pathways contribute to the resistance of NSCLC to first- and third-generation EGFR-TKIs, such as erlotinib and osimertinib. osimertinib 151-162 ret proto-oncogene Homo sapiens 9-33 34203709-2 2021 Multiple receptor tyrosine kinase (RTK) pathways contribute to the resistance of NSCLC to first- and third-generation EGFR-TKIs, such as erlotinib and osimertinib. osimertinib 151-162 ret proto-oncogene Homo sapiens 35-38 35066105-7 2022 RESULTS: Among the 45 patients included in MATCH-R who progressed on osimertinib, nine developed a second targetable alteration (n = 2 FGFR3-TACC3, n = 1 KIF5B-RET, n = 1 STRN-ALK fusions; n = 2 BRAFV600E, n = 1 KRASG12V, n = 1 KRASG12R, n = 1 KRASG12D mutations). osimertinib 69-80 ret proto-oncogene Homo sapiens 160-163